Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.63 |
| ▸ | ILK | Q13418 | 3/20 | 0.63 |
| ▸ | FBP1 | P09467 | 4/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | BUB1 | O43683 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646428 | 0.89 | EGFR (0.70) | EGFRILKFBP1ERBB2KDR | |
| SCHEMBL13646413 | 0.89 | EGFR (0.63) | EGFRILKFBP1ERBB2KDR | |
| Erlotinib SCHEMBL13087124 | 0.83 | EGFR (0.78) | EGFRILKFBP1ERBB2KDR | |
| SCHEMBL13646432 | 0.82 | EGFR (0.75) | EGFRILKFBP1ERBB2KDR | |
| SCHEMBL3871041 | 0.82 | EGFR (0.59) | EGFRILKFBP1ERBB2KDR | |
| SCHEMBL3875041 | 0.82 | EGFR (0.71) | EGFRILKFBP1ERBB2KDR | |
| SCHEMBL13646438 | 0.81 | EGFR (0.55) | EGFRILKERBB2KDRKDM1A | |
| SCHEMBL13646435 | 0.79 | FBP1 (0.71) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL13646431 | 0.79 | FBP1 (0.70) | EGFRILKFBP1ERBB2KDR | |
| SCHEMBL23264520 | 0.77 | EGFR (1.00) | EGFRILKFBP1ERBB2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885ILK 2741/4885FBP1 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.